CN109563151B - 用于治疗癌症的方法和组合物 - Google Patents

用于治疗癌症的方法和组合物 Download PDF

Info

Publication number
CN109563151B
CN109563151B CN201780043683.0A CN201780043683A CN109563151B CN 109563151 B CN109563151 B CN 109563151B CN 201780043683 A CN201780043683 A CN 201780043683A CN 109563151 B CN109563151 B CN 109563151B
Authority
CN
China
Prior art keywords
seq
polypeptide
arg
lys
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780043683.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109563151A (zh
Inventor
劳拉·索切克
托尼·尧塞特冈萨雷斯
马里-埃韦·比利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Publication of CN109563151A publication Critical patent/CN109563151A/zh
Application granted granted Critical
Publication of CN109563151B publication Critical patent/CN109563151B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780043683.0A 2016-07-15 2017-07-17 用于治疗癌症的方法和组合物 Active CN109563151B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382339.6A EP3269734A1 (en) 2016-07-15 2016-07-15 Methods and compositions for the treatment of cancer
EP16382339.6 2016-07-15
PCT/EP2017/067998 WO2018011433A1 (en) 2016-07-15 2017-07-17 Methods and compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
CN109563151A CN109563151A (zh) 2019-04-02
CN109563151B true CN109563151B (zh) 2023-03-07

Family

ID=56497695

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780043683.0A Active CN109563151B (zh) 2016-07-15 2017-07-17 用于治疗癌症的方法和组合物

Country Status (21)

Country Link
US (1) US11427621B2 (enExample)
EP (2) EP3269734A1 (enExample)
JP (1) JP7090593B2 (enExample)
KR (1) KR102232500B1 (enExample)
CN (1) CN109563151B (enExample)
AU (1) AU2017295071B2 (enExample)
BR (1) BR112019000732A2 (enExample)
EA (1) EA201990298A1 (enExample)
ES (1) ES2985967T3 (enExample)
HR (1) HRP20241153T1 (enExample)
HU (1) HUE067973T2 (enExample)
IL (1) IL264176B2 (enExample)
MA (1) MA45675B1 (enExample)
MD (1) MD3484913T2 (enExample)
MX (1) MX2019000346A (enExample)
PL (1) PL3484913T3 (enExample)
RS (1) RS65983B1 (enExample)
SG (1) SG11201900021PA (enExample)
SM (1) SMT202400360T1 (enExample)
WO (1) WO2018011433A1 (enExample)
ZA (1) ZA201900960B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101729826B1 (ko) * 2015-01-09 2017-05-11 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101859583B1 (ko) * 2016-07-07 2018-06-27 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101862239B1 (ko) * 2016-07-07 2018-05-30 주식회사 동희산업 플라스틱 연료탱크의 제조방법
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
EP3841114A4 (en) * 2018-08-20 2022-06-08 Helix Nanotechnologies, Inc. METHODS AND COMPOSITIONS FOR RNA EXPRESSION OF MYC INHIBITORS
TWI829893B (zh) 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
WO2020187998A1 (en) * 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
KR102398339B1 (ko) * 2020-01-09 2022-05-13 이화여자대학교 산학협력단 일산화질소 전달용 융합 펩타이드 및 이의 용도
CN115397843A (zh) * 2020-04-15 2022-11-25 杭州卫本医药科技有限公司 用于筛选药物的靶标多肽和筛选方法
EP4361633A1 (en) 2022-10-25 2024-05-01 Peptomyc, S.L. Method for predicting response to a cancer treatment
EP4446742A1 (en) 2023-04-14 2024-10-16 Peptomyc, S.L. Method for assessing or monitoring the response to a cancer treatment
EP4473974A1 (en) * 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014180889A1 (en) * 2013-05-07 2014-11-13 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Methods and compositions for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
JPH11510389A (ja) 1995-07-31 1999-09-14 アメリカ合衆国 細胞タンパク質の機能を不活性化するためのタンパク質−タンパク質相互作用表面の拡張
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
EP1044021B1 (en) 1998-01-05 2009-09-23 The University of Washington Enhanced transport using membrane disruptive agents
AU767195B2 (en) 1999-03-10 2003-11-06 Phogen Limited Delivery of substances to cells
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US9241920B2 (en) * 2011-10-27 2016-01-26 New York University Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014180889A1 (en) * 2013-05-07 2014-11-13 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Methods and compositions for the treatment of cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
《AAQ57178.1》;NCBI;《GenBank》;20041007;第1页 *
《EHB05990.1》;NCBI;《GenBank》;20150314;第1-2页 *
《Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice》;Laura Soucek等;《Genes & Development》;20130301;第27卷(第5期);第504-513页 *
《Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis》;Daniela Annibali等;《Nature Communications》;20140818(第5期);第4632篇 *
《Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis》;Laura Soucek等;《Cancer Research》;20020615;第62卷(第12期);第3507-3510页 *
《XP_003516054.2》;NCBI;《GenBank》;20140430;第1页 *
NCBI.《EHB05990.1》.《GenBank》.2015,第1-2页. *

Also Published As

Publication number Publication date
KR20190032427A (ko) 2019-03-27
US20200247857A1 (en) 2020-08-06
ES2985967T3 (es) 2024-11-08
EA201990298A1 (ru) 2019-06-28
HUE067973T2 (hu) 2024-11-28
US11427621B2 (en) 2022-08-30
MA45675B1 (fr) 2024-07-31
BR112019000732A2 (pt) 2019-07-30
MD3484913T2 (ro) 2024-10-31
EP3484913B1 (en) 2024-07-03
ZA201900960B (en) 2020-05-27
HRP20241153T1 (hr) 2024-11-22
JP2019525753A (ja) 2019-09-12
SMT202400360T1 (it) 2024-11-15
EP3484913C0 (en) 2024-07-03
AU2017295071A1 (en) 2019-01-31
RS65983B1 (sr) 2024-10-31
WO2018011433A1 (en) 2018-01-18
MX2019000346A (es) 2019-04-01
KR102232500B1 (ko) 2021-03-26
SG11201900021PA (en) 2019-01-30
IL264176B2 (en) 2023-07-01
JP7090593B2 (ja) 2022-06-24
MA45675A (fr) 2021-04-21
PL3484913T3 (pl) 2025-01-07
IL264176B1 (en) 2023-03-01
EP3484913A1 (en) 2019-05-22
EP3269734A1 (en) 2018-01-17
IL264176A (en) 2019-02-28
CA3029781A1 (en) 2018-01-18
AU2017295071B2 (en) 2022-06-09
CN109563151A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
CN109563151B (zh) 用于治疗癌症的方法和组合物
KR102324116B1 (ko) 암의 치료를 위한 방법 및 조성물
CA3086768C (en) Atf5 peptide variants and uses thereof
CA3029781C (en) Methods and compositions for the treatment of cancer
EA042570B1 (ru) Способы и композиции для лечения рака
HK40007694B (en) Methods and compositions for the treatment of cancer
HK40007694A (en) Methods and compositions for the treatment of cancer
HK40040895B (en) Atf5 peptide variants and uses thereof
HK40040895A (en) Atf5 peptide variants and uses thereof
EA047076B1 (ru) Способы и композиции для лечения рака
HK1219756B (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment